cells in vitro (9) . Targeting EGFR via several different approaches, including suppression of EGFR mRNA using antisense oligonucleotides, and blocking the function of the mature protein at two sites, the ligand-binding domain and the kinase domain, we previously demonstrated inhibition of proliferation of SCCHN but not normal mucosal squamous epithelial cells (10) . To extend our in vitro observations to an in vivo model, we have generated antisense (and sense) expression plasmid constructs targeting EGFR designed for direct intratumoral injection with DC-Chol cationic liposomes, i.e., 3␤[N-NЈ,NЈ-(dimethylaminoethane)-carbamoyl] cholesterol. Our goals in choosing a gene transfer vector were to: 1) transfect a large proportion of tumor cells in vivo; 2) generate high expression levels of antisense RNA in each cell; and 3) demonstrate an antitumor response following treatment. To accomplish this, we selected the U6 small nuclear RNA (snRNA) promoter that has been engineered to express short antisense RNA sequences under the control of RNA polymerase III (11) and which we have previously used to inhibit cervical carcinoma tumor growth in vitro and in vivo via antisense RNA targeting of human papilloma virus (HPV) 16 E6 and E7 oncogenes (12) . In this study, we have cloned EGFR antisense oligonucleotides into a modified U6 expression construct and demonstrated sustained antitumor efficacy and suppression of EGFR protein expression following intratumoral delivery of the antisense plasmid DNA/ liposome complex.
Materials and Methods
Plasmid construct and cloning. In the original U6 expression plasmid (pGEMmU6; from S. Noonberg, University of California San Francisco Cancer Research Institute), the U6 expression cassette contains the U6 promoter, enhancer, and the mutated U6 structural sequence (11) . The first 24 and the last 18 nucleotides of the U6 structural sequence remain, while the middle region has been replaced with a 38-base-pair (bp) oligonucleotide fragment containing Xho I and Nsi I sites for convenient cloning. The U6 RNA produced from this vector contains a hairpin loop motif at the 5Ј end that is responsible for capping of the U6 RNA. Since it has been recently demonstrated that capping of transcripts is not required for nuclear retention (13) , we eliminated the sequences containing this motif (from nucleotide 7-24 by polymerase chain reaction (PCR)-mediated deletion) to minimize the flanking sequence around the antisense gene. Forty-bp long sense and antisense oligonucleotides corresponding to the ATG start site of the human EGFR gene (−20 to +20) were synthesized and cloned into the Xho I and Nsi I sites of the new plasmid, p᭝HU6, and the sequences were verified by sequence analysis (Fig. 1) .
Cells and tumors. The cell line, 1483, is a well-described SCCHN cell line derived from a tumor of the retromolar trigone region of the oropharynx (14) In vivo tumor xenograft studies. The 1483 cell line reportedly grows well as xenografts in nude mice (15) . Cells in log phase (1483) were harvested by trypsinization, resuspended in DMEM media supplemented with 10% FCS, centrifuged at 1000 rpm for 10 minutes, and resuspended in culture media at a concentration of 1 × 10 7 cells/mL prior to subcutaneous implantation into mice. Female athymic nude mice nu/nu (4-6 weeks old; 20 ± 2 g [standard deviation]; Harlan Sprague-Dawley, Inc., Indianapolis, IN) were implanted with 1 × 10 6 cells into the right flank with a 26-gauge needle/1 mL tuberculin syringe. Approximately 14-21 days later when the tumor nodules were palpable (∼2 × 2 mm in diameter), mice were randomly assigned to treatment groups (liposomes alone, p᭝HU6-EAS [EGFR antisense U6 construct] alone, p᭝HU6-EAS plus liposomes, or p᭝HU6-ES [EGFR sense U6 construct] plus liposomes). There were eight to 10 mice in each treatment group in an individual experiment. Experiments were repeated three times to insure reproducibility. Intratumoral injection of plasmid DNA (50 g) complexed with DC-Chol liposomes (50 nmol) in a volume of 50 L (three times a week for 19 days) was instituted approximately 14-21 days after tumor implantation or when the tumors were palpable (∼2 × 2 mm). Tumors were measured using calipers prior to each injection (three times a week) and tumor volumes were calculated (tumor volume ‫ס‬ length × width 2 /2; fractional tumor volume calculated as a proportion of the pretreatment tumor volume). Mice where killed when the tumors ulcerated or reached a maximum diameter of 2 cm. Animal care was in strict compliance with institutional guidelines established by the University of Pittsburgh, the Guide for the Care and Use of Laboratory Animals (National Academy of Sciences, 1996) , and the Association for Assessment and Accreditation of Laboratory Animal Care International.
Transfection. In vitro transient transfection was accomplished using plasmid DNA (3 g) complexed with lipofectamine (10 g/mL) (Life Technologies, Inc.) according to the manufacturer's instructions. DC-Chol liposomes were prepared by our laboratory for in vivo delivery of plasmid DNA as described (16) .
Reverse-transcription-polymerase chain reaction (RT-PCR). To detect the U6 antisense chimeric RNA in the tumor following intratumoral injection of the plasmid-liposome complex, total RNA was extracted from the harvested xenografts as described previously (12) . One microgram of the total RNA was digested with 1 U of ribonuclease (RNase)-free deoxyribonuclease (DNase) (Life Technologies, Inc.). Complementary DNA (cDNA) was synthesized using avian myeloblastosis virus (AMV) reverse transcriptase and the backward primer complementary to the 3Ј end of the U6 RNA and U6/antisense chimeric RNA using Access RT-PCR Kit (Promega Corp., Madison, WI). PCR was performed on the cDNA using the primers for U6 RNA and U6 chimeric RNA under the conditions recommended by the manufacturer. The PCR products were fractionated on 12% polyacrylamide gel electrophoresis (PAGE) gel and blotted to nitrocellulose membrane (MSI, Westboro, MA). Hybridization of the blot with 32 P-labeled EGFR oligonucleotides was performed as described previously (17) . To make sure that the fragment amplified by PCR was not due to residual DNA contamination, PCR was also performed under the same conditions on the RNase-free DNase-treated RNA samples without adding the AMV reverse transcriptase.
Immunoblotting. Fresh tissue or cell lines were lysed in detergent containing 1% NP-40, 0.1 mM phenylmethyl sulfonyl fluoride, 1 mg/mL leupeptin, and 1 mg/mL aprotinin, and protein levels were determined using the Bio-Rad Protein Assay method (Bio-Rad Laboratories, Hercules, CA). Fifty micrograms of total protein was separated on a 10% sodium dodecyl sulfate-PAGE and transferred to nitrocellulose membranes using semi-wet blotting. Filters were blocked with a 5% bovine serum albumin/Tris-buffered saline with Tween 20 (TBST) solution overnight, rinsed three times in TBST, and incubated 90 minutes with a mouse anti-human EGFR monoclonal antibody (Transduction Labs, Lexington, KY). Membranes were then incubated for 45 minutes with an horseradish peroxidaseconjugated secondary antibody (Bio-Rad Laboratories). Enhanced chemiluminescence (Amersham Life Science Inc., Arlington Heights, IL) technology was used to detect EGFR signal. Membranes were exposed to Kodak X-OMAR film (Eastman Kodak Co., Rochester, NY) for 15 seconds.
Immunohistochemistry. Tumor specimens (SCCHN xenografts) were fixed immediately following resection in 10% buffered neutral formalin and stained with hematoxylin-eosin for histopathologic analysis. Indirect immunohistochemical staining for EGFR (Cambridge Research/Genosys Biotechnologies, The Woodlands, TX) was performed on paraffin-embedded tissues using a murine monoclonal antibody from a commercially available assay. The labeled streptavidin-biotin (LSAB) method was used to visualize antibody positivity (DAKO LSAB + kits, DAKO Corp., Carpinteria, CA). The primary antibody was a mouse antihuman immunoglobulin G (IgG) against the extracellular domain of the receptor (Transduction Labs). The secondary antibody was a horse antimouse biotinylated IgG (Bio-Rad Laboratories). Brown staining was considered positive. Positive and negative controls were as described previously (18) . Specimens were interpreted independently by two histopathologists blinded to treatment status of the tumors.
Apoptosis determinations/DNA fragmentation. The percentage of apoptotic cells in tumors treated with the constitutive EGFR antisense (versus sense) U6-based construct was determined by staining for DNA fragmentation (Apotaq). Tumors were harvested, sectioned, fixed in formalin and paraffin embedded, then incubated with proteinase K diluted in phosphate-buffered saline (PBS) for 20 minutes and washed four times in water. Slides were then incubated in 3% H 2 O 2 in PBS for 5 minutes and washed twice in PBS. Each section was incubated with a terminal transferase enzyme that catalyzes the addition of digoxigenin-labeled nucleotides to the 3Ј-OH ends of the fragmented DNA for 15 minutes at 37°C. Slides were then placed in stop buffer for 30 minutes at 37°C, followed by washing three times in PBS for 5 minutes. Negative controls are obtained by substituting dH 2 O for the terminal deoxynucleotidyl transferase mix. Slides were read and scored under 400× magnifications for the number of positive cells per five high-power fields using computerized image analysis (SAMBA 4000 Image Analysis System; Image Products International, Chantilly, VA).
Statistical analysis. For in vivo experiments in which tumor volumes of the same mice were measured over time, the statistical significance of differences between groups was examined by use of repeated measures analysis of variance (two-sided). Comparisons were restricted to mice in the same experiment. For apoptosis studies, the statistical significance of differences in apoptosis rates was assessed by use of Student's t test (two-sided) that assumed unequal variance.
Results
Modification of U6 expression plasmid. U6 is a small, stable RNA that exists as an abundant small nuclear ribonucleoprotein (U6 snRNP) in all human cells where it plays central roles in both spliceosome assembly and catalysis in nuclear premessenger RNA splicing. Compared with other Pol IIItranscribed gene promoters, such as transfer RNA, the U6 promoter has no control regions located within the sequence encoding the structural component of the RNA. Thus, nearly all of the structural U6 core can be replaced with any other sequence without affecting transcript production (19) . A modified U6 expression vector, p᭝HU6, was generated from the parental plasmid, pGEMmU6 11 by deleting the 5Ј hairpin loop through PCRmediated deletion. The deletion was verified by sequence analysis (data not shown). Oligonucleotides (40 bp) targeting the ATG start site of the human EGFR gene was cloned into plasmid p᭝HU6 in the sense (p᭝HU6-ES) or antisense (p᭝HU6-EAS) orientation (Fig. 1) .
Antitumor efficacy of antisense EGFR/U6 chimeric construct. To determine whether treatment of established tumors with the EGFR antisense gene expression vector resulted in inhibition of tumor growth, we developed a xenograft model using 1483 cells inoculated subcutaneously in nude mice. DCChol cationic liposomes were selected, since they have been shown to be an effective gene transfer vehicle without inducing inflammation in animals (20) . Mice were treated three times a week and killed 19 days later when the tumors in the control group(s) had reached 2 cm in maximum diameter. A group of mice were treated with EGFR antisense DNA alone to determine the necessity of the liposomal transfer vehicle. Mice that received the antisense construct plus liposomes were killed at intervals up to 33 days to determine the persistence of the antisense effects. On killing the mice, actual tumor volumes and fractional tumor volumes were calculated and at nearly all time points, tumor volumes were significantly lower in the mice that received the EGFR antisense construct (plus liposomes) than in the mice that received the corresponding sense construct (plus liposomes) (Fig. 2) . Dose-response studies were also performed and 25 g of EGFR antisense DNA (plus 25 nmol of DC-Chol liposomes) was found to be as effective as 50 g/injection in inhibiting tumor growth. A lower dose of 2.5 g was only modestly effective and 0.25 g did not abrogate tumor growth (data not shown). There was no difference between actual or fractional tumor volumes in the mice treated with liposomes alone compared with the sense construct plus liposomes or the antisense construct alone. Furthermore, the antitumor effect of the antisense therapy was sustained for up to 14 days following cessation of treatment (data not shown). The need for liposomes to mediate gene transfer was verified by the failure to observe growth inhibition in the tumors treated with EGFR antisense DNA alone.
Chimeric U6/EGFR antisense gene expression in SCCHN cells. To determine the expression levels of the chimeric antisense (and sense) genes in 1483 cells in vitro, cells were treated with the plasmids p᭝HU6-EAS or p᭝HU6-ES plus lipofectamine. The conditions for transfection (e.g., cell density and lipofectamine concentration) were established for 1483 cells using CMV-LacZ gene delivery and X-gal staining (data not shown). Two days later, total RNA was extracted and primer extension analysis was performed to determine levels of chimeric gene expression (antisense or sense) in transiently transfected cells in vitro. Since the primer used can hybridize to both the endogenous U6 snRNA and the U6/EGFR chimeric RNA, the amount of endogenous U6 snRNA can be used as a normalization control to quantify chimeric gene expression (approximately 0.5 million copies per cell for the endogenous U6 snRNA). The number amount of U6/EGFR chimeric RNA copies per cell was calculated to be 6.3 × 10 5 for the EGFR antisense chimeric RNA and 1.6 × 10 6 for the corresponding sense chimeric RNA 2 days after transfection (approximately 0.5 million copies per cell for the endogenous U6 snRNA). The chimeric RNA was easily detected up to 1 week after transfection (data not shown). To determine chimeric gene expression in vivo, tumors treated with the plasmids p᭝HU6-EAS or p᭝HU6-ES plus DC-Chol liposomes were harvested, RNA was extracted, and RT-PCR was performed followed by hybridization with labeled oligonucleotides to the EGFR chimeric genes (sense or antisense). As shown in Fig. 3 , all of the tumors treated with sense or antisense constructs expressed the appropriate chimeric gene in contrast to the tumors treated with liposomes alone. Since residual DNA may contaminate and give false- positive RT-PCR results, we also ran the PCR reaction without adding AMV reverse transcriptase. The result of the PCR amplification was negative on all of the RNA samples treated with RNase-free DNase (data not shown). This indicated that the RNA samples were free of DNA contamination and that the positive signal detected after RT-PCR came from the U6/ chimeric RNA.
Suppression of EGFR gene expression in antisensetransfected cells and antisense-treated tumors.
To determine that the growth inhibitory effects detected with EGFR antisense treatment were associated with suppression of target (EGFR) gene expression, tumors were harvested and immunoblotting was performed. Treatment with the EGFR antisense expression construct resulted in suppression of EGFR protein expression (Fig. 4) . To verify that the suppression in the intact tumor was due to decreased expression in the tumor cells, EGFR immunostaining was performed that demonstrated decreased EGFR staining intensity in the transformed epithelial cells of the antisense-treated tumors (Fig. 5, A-C) . Since intact tumors do not represent a pure population of transformed epithelial cells, 1483 cells in vitro were transiently transfected with the EGFR antisense (or sense) construct followed by EGFR immunoblotting. EGFR antisense treatment of these cells in vitro also demonstrated suppression of EGFR protein expression by immunoblotting (Fig. 6) .
Increased apoptosis in tumors treated with the antisense EGFR construct. To investigate the mechanism of the antitumor effect induced by treatment with the EGFR antisense construct plus liposomes, we examined hematoxylin-eosin staining of the xenografts and were unable to detect a difference in tumor necrosis between treatment groups (data not shown). To determine whether the observed growth inhibition was associated with an increased rate of programmed cell death, tumors were harvested from each treatment group when the mice were killed (10 mice/group) and stained for DNA fragmentation (Apotaq).
Results demonstrated approximately threefold elevation in the rate of apoptosis in tumors treated with the EGFR antisense construct plus liposomes compared with tumors treated with the corresponding sense construct plus liposomes or liposomes alone (two-sided, P ‫ס‬ .007; Figs. 7 and 8)
Discussion
The data presented here demonstrate efficient liposomalmediated transfection of SCCHN cells with an antisense EGFR expression construct under the control of the U6 snRNA promoter in vivo. High expression levels of the chimeric U6 constructs were detected in the tumor cells following treatment of tumor-bearing mice with the EGFR antisense construct plus DCChol liposomes, which resulted in sustained growth inhibition, even after the treatments were discontinued. This antitumor effect was accompanied by down-regulation of EGFR protein expression in the tumor cells and increased apoptosis. We did not specifically address the mechanism of EGFR down-regulation.
Epithelial cell transformation has been associated with high expression levels of EGFR and its activating ligand (e.g., TGF-␣), which suggests that an autocrine growth pathway may be operating in this tumor system (21, 22) . We and others (23) (24) (25) (26) have demonstrated that SCCHN cells that overexpress EGFR also produce elevated levels of TGF-␣. In such cells, blocking EGFR activation using several strategies, including antisense oligonucleotides, monoclonal antibodies, or EGFR-specific tyrosine kinase inhibitors, resulted in inhibition of SCCHN but not normal epithelial cell proliferation (10) . This difference in response to EGFR blocking strategies in normal compared with transformed mucosal squamous epithelial cells may be due to the relatively small number of EGF receptors in normal mucosa. Alternatively, TGF-␣/EGFR may be participating in a nonproliferative pathway in normal epithelium as reflected by the primarily suprabasal localization of TGF-␣ in normal mucosa from patients without cancer in contrast to production by basal, proliferating epithelial cells in normal mucosa harvested several centimeters away from the tumor in patients with SCCHN (18). In panel A, representative immunoblotting of EGFR protein expression in tumors from mice treated with the EGFR antisense construct (plus liposomes), the EGFR sense construct (plus liposomes), or liposomes alone (control) from an individual experiment that was replicated three times. Crude protein lysates were isolated from each tumor and 50 g per sample was separated on 10% sodium dodecyl sulfate-polyacrylamide gel electrophoresis that was blotted with mouseanti-human EGFR monoclonal antibody (Transduction Labs).
The failure to inhibit proliferation of normal squamous epithelial cells using EGFR blocking strategies suggests that treatments that target EGFR in SCCHN may result in antitumor effects with minimal toxicity when administered in the region of the carcinoma.
Potential mechanisms of tumor growth inhibition include necrosis and apoptosis. We investigated these possibilities by examining the treated tumors for morphologic features of necrosis on hematoxylin-eosin staining and found no appreciable difference among the treatment groups. However, when the treated tumors were stained for DNA fragmentation, we found a significantly elevated rate of apoptosis in the tumors treated with the EGFR antisense construct plus liposomes compared with tumors receiving the corresponding sense construct plus liposomes. Others (27) have reported elevated apoptosis in transformed epithelial cell lines in vitro following treatment with an anti-EGFR monoclonal antibody.
EGFR overexpression has been implicated as a prognostic indicator in numerous cancers (28) . Cancer treatments that target EGFR have been designed to inhibit tumor growth and improve outcome. Although we did not specifically test this antisense construct in other tumor models, it should theoretically be effective for EGFR-overexpressing tumors where EGFR signaling is associated with a proliferative pathway. Several strategies have been previously employed to inhibit EGFR, including monoclonal antibodies and immunotoxins linked to an EGFR ligand such as TGF-␣. Although these therapies have resulted in minimal toxicity, limited antitumor effects have been observed in the clinical setting most likely due to the requirement for systemic administration and generation of a host immune response (29) .
Nonviral vector-mediated gene transfer has several theoretical advantages over virally mediated transfer, including low toxicity, lack of immunogenicity and inflammatory reactions, and the relative ease of obtaining large quantities of vector (20) . Cationic liposomes contain a positively charged amine head group linked to a hydrophobic chain. The positively charged group can complex with DNA through the electrostatic charge interaction and the liposome-DNA complex is taken up by the cells through endocytosis. DC-Chol contains a tertiary amine head and a cholesterol linked by a carbamoyl bond (30) . It can form a liposome with the helper lipid DOPE. DC-Chol liposomes have been used in several clinical trials with negligible toxicity reported, including the delivery of the allogeneic MHC (major histocompatibility complex) gene into melanoma tumor sites and CFTR (cystic fibrosis transmembrane conductance regulator) gene transfer into nasal epithelia of patients with cystic fibrosis (31, 32) . We demonstrate here that direct inoculation of an EGFR antisense construct complexed with cationic liposomes into the tumor resulted in inhibition of tumor growth. SCCHN tumor sites are relatively accessible to direct inoculation (e.g. oral cavity, oropharynx, hypopharynx, and larynx). The regional cervical lymphatics that comprise the initial (and frequently only) metastatic site are also readily amenable to direct inoculation as demonstrated by other therapeutic approaches that have relied on this route of administration (33, 34) .
Antisense-based gene therapy approaches to cancer rely on the disruption of target gene expression that is thought to be critical for tumor cell proliferation. However, the factors that affect the efficacy of the antisense molecule are largely unknown (35) . Variables that might be considered when designing antisense expression vectors include the following: 1) the concentration of the antisense RNA within the cells must be sufficiently high to lead to the hybridization of the antisense RNA to its target; 2) the antisense RNA produced from the expression vector should not contain excessive flanking sequences that might interfere with the accessibility to target RNA; and 3) the length of the antisense RNA should be designed for maximal efficacy. To achieve an optimal antisense strategy, we cloned relatively short (40 bp) antisense oligonucleotides targeting the translation start site of the human EGFR gene into a modified U6 snRNA construct where we deleted the hairpin loop motif to improve access to target RNA. U6 snRNA expression system offers several theoretical advantages over more commonly used gene transfer vehicles that utilize RNA polymerase II-transcribed promoters (e.g., cytomegalovirus), including 1) U6 snRNA is constitutively expressed in all mammalian cells (0.5 million copies/ cell) (36) and we have previously demonstrated that the U6 promoter can generate a large amount of short RNA (12); 2) the U6 promoter contains no internal control region thereby allowing replacement of nearly all of the U6 gene with sequence(s) encoding antisense RNA; 3) only a few nucleotides on the 5Ј end of U6 RNA are required for the synthesis and stability of U6 chimeric RNA thus reducing the likelihood of internal folding of the flanking sequence onto the antisense RNA and interference with binding to the target (37); and 4) U6 RNA is retained in the nucleus allowing for targeting of premessenger RNA 11, 13 . Previous studies (38, 39) have demonstrated that the first 24 nucleotides in the U6 snRNA that can form a hairpin loop are required for the post-transcriptional modification and thus the stability of the U6 snRNA. However, in our hands, deletion of this domain did not decrease the amount of chimeric RNA expression in the cell (unpublished data). Since the 5Ј end hairpin loop could theoretically affect the accessibility of the antisense RNA to the target, we deleted this domain to generate a novel expression vector for these studies. Our results shown here verify that the U6 expression vector without a 5Ј hairpin loop is stable and can generate a large amount of U6/chimeric antisense RNA intracellularly.
